First 'QIDP' designated antibiotic gets US market approval
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has approved the first drug under a provision of the Generating Antibiotic Incentives Now (GAIN) Act that makes it possible for companies to receive priority review, fast-track status and an additional five years of market exclusivity1,2.